Reviewed by Michael Gill, B. Sc.
25 Pcos Clinical Trials Near Me
Top Hospitals for Pcos Clinical Trials
Image of University of Virginia in Virginia.
University of Virginia
Charlottesville
6Active Trials
7All Time Trials for Pcos
2000First Pcos Trial
Image of University of Virginia Center for Research in Reproduction in Virginia.
University of Virginia Center for Research in Reproduction
Charlottesville
4Active Trials
8All Time Trials for Pcos
2006First Pcos Trial
Top Cities for Pcos Clinical Trials
Image of Oklahoma City in Oklahoma.
Oklahoma City
2Active Trials
University of OklahomaTop Active Site
Most Recent Pcos Clinical Trials
Top Treatments for Pcos Clinical Trials
Treatment Name
Active Pcos Clinical Trials
All Time Trials for Pcos
First Recorded Pcos Trial
Spironolactone
3
5
2016
Flutamide
3
5
2006
Metformin
3
71
2000
Progesterone
2
6
2000
Tildacerfont
1
1
2022

What Are PCOS Clinical Trials?

PCOS is a common health problem in women; however, it is a common and treatable cause of infertility. Women with PCOS face hormonal imbalances and metabolism problems that affect their appearance and overall health. In this condition, the ovaries produce an abnormal amount of androgens, which are male sex hormones present in women in small amounts. Some women develop fluid-filled sacs, called cysts, in their ovaries, while some don’t.

Since the cause of PCOS is unclear, many PCOS clinical trials study different drugs and therapies and analyze their effectiveness against the condition.

Why Is PCOS Being Studied Through Clinical Trials?

The global prevalence of PCOS is estimated between 4% and 20%. In contrast, the World Health Organization (WHO) data suggests that approximately 116 million women (3.4%) are affected by PCOS globally. The reasons for PCOS development are not yet clearly identified. Researchers suggest that multiple factors, such as hereditary, lifestyle, and environmental, can contribute to the condition.

Women with PCOS face irregular or anovulatory cycles with signs of hyperandrogenism, such as acne, seborrhea, hirsutism, alopecia, and polycystic ovaries on pelvic sonography. Patients also experience mood swings, weight gain, and pregnancy-related issues.

What Are The Types of Treatments Available For PCOS?

Many ongoing studies are available for PCOS, testing different drugs and their effectiveness. As stated above, the fundamental pathological defect of PCOS is unknown, but we do know that it is characterized by insulin resistance and compensatory hyperinsulinemia. A study evaluates the safety and effectiveness of 3 drugs: clomiphene, citrate, and metformin XR, in achieving a successful pregnancy in infertile PCOS women.

Other studies compare and analyze the clinical outcomes between treatments, such as hCG-primed IVM protocol and minimal stimulation IVF with Gonadotropin-releasing hormone (GnRH) antagonist protocol in women with PCOS in fresh cycles.

What Are Some Recent Breakthrough Clinical Trials For PCOS?

2019: Myo-Inositol/D-Chiro-Inositol Plasma Ratio - this clinical trial directly compared the efficacy of seven different ratios between MI and DCI in PCOS therapy. The authors found that the 40 : 1 MI/DCI ratio was the best for PCOS therapy directed at restoring ovulation and important normalizing parameters (progesterone, LH, SHBG, estradiol, and testosterone) in those patients.

2021: Caesalpinia bonduc (L.) Roxb. - this study reviewed the potential of Caesalpinia bonducella in treating the significant symptoms of PCOS. Phytochemicals in C. bonducella are effective against several ailments attributed to PCOS. However, there are no experiments done in PCOS animal models to claim the direct application of C. bonducella in PCOS treatment.

Who Are Some Of The Key Opinion Leaders / Researchers / Institutions Conducting PCOS Clinical Trial Research?

UCSF Center Of Reproductive Health

The UCSF Polycystic Ovary Syndrome (PCOS) Multidisciplinary Clinic and Research Center has made great strides in optimizing health and quality of life in women with PCOS. They have developed individualized treatment plans, drug therapies, and lifestyle interventions.

Andrea Dunaif, M.D.

Andrea Dunaif, M.D., is the System Chief of the Division of Endocrinology, Diabetes, and Bone Disease for the Mount Sinai Health System. Her research on polycystic ovary syndrome (PCOS) has shown that it is a leading risk factor for type 2 diabetes mellitus.

About The Author

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 2nd, 2021

Last Reviewed: November 18th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.

References1 Tasali E, Leproult R, Ehrmann DA, Van Cauter E. Slow-wave sleep and the risk of type 2 diabetes in humans. Proc Natl Acad Sci U S A. 2008 Jan 22;105(3):1044-9. doi: 10.1073/pnas.0706446105. Epub 2008 Jan 2. https://pubmed.ncbi.nlm.nih.gov/181722122 Ehrmann DA, Liljenquist DR, Kasza K, Azziz R, Legro RS, Ghazzi MN; PCOS/Troglitazone Study Group. Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2006 Jan;91(1):48-53. Epub 2005 Oct 25. https://pubmed.ncbi.nlm.nih.gov/162492843 Lippincott MF, León S, Chan YM, Fergani C, Talbi R, Farooqi IS, Jones CM, Arlt W, Stewart SE, Cole TR, Terasawa E, Hall JE, Shaw ND, Navarro VM, Seminara SB. Hypothalamic Reproductive Endocrine Pulse Generator Activity Independent of Neurokinin B and Dynorphin Signaling. J Clin Endocrinol Metab. 2019 Oct 1;104(10):4304-4318. doi: 10.1210/jc.2019-00146. https://pubmed.ncbi.nlm.nih.gov/311321184 González F. Nutrient-Induced Inflammation in Polycystic Ovary Syndrome: Role in the Development of Metabolic Aberration and Ovarian Dysfunction. Semin Reprod Med. 2015 Jul;33(4):276-86. doi: 10.1055/s-0035-1554918. Epub 2015 Jul 1. Review. https://pubmed.ncbi.nlm.nih.gov/261329325 Sopher AB, Grigoriev G, Laura D, Cameo T, Lerner JP, Chang RJ, McMahon DJ, Oberfield SE. Anti-Mullerian hormone may be a useful adjunct in the diagnosis of polycystic ovary syndrome in nonobese adolescents. J Pediatr Endocrinol Metab. 2014 Nov;27(11-12):1175-9. doi: 10.1515/jpem-2014-0128. https://pubmed.ncbi.nlm.nih.gov/250033766 Sopher AB, Gerken AT, Blaner WS, Root JM, McMahon DJ, Oberfield SE. Metabolic manifestations of polycystic ovary syndrome in nonobese adolescents: retinol-binding protein 4 and ectopic fat deposition. Fertil Steril. 2012 Apr;97(4):1009-15. doi: 10.1016/j.fertnstert.2012.01.111. Epub 2012 Feb 17. https://pubmed.ncbi.nlm.nih.gov/223418817 Pau CT, Keefe C, Duran J, Welt CK. Metformin improves glucose effectiveness, not insulin sensitivity: predicting treatment response in women with polycystic ovary syndrome in an open-label, interventional study. J Clin Endocrinol Metab. 2014 May;99(5):1870-8. doi: 10.1210/jc.2013-4021. Epub 2014 Feb 25. https://pubmed.ncbi.nlm.nih.gov/246060938 Tasali E, Van Cauter E, Ehrmann DA. Relationships between sleep disordered breathing and glucose metabolism in polycystic ovary syndrome. J Clin Endocrinol Metab. 2006 Jan;91(1):36-42. Epub 2005 Oct 11. https://pubmed.ncbi.nlm.nih.gov/162197199 Tasali E, Chapotot F, Leproult R, Whitmore H, Ehrmann DA. Treatment of obstructive sleep apnea improves cardiometabolic function in young obese women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2011 Feb;96(2):365-74. doi: 10.1210/jc.2010-1187. Epub 2010 Dec 1. https://pubmed.ncbi.nlm.nih.gov/2112344910 O'Mara AE, Johnson JW, Linderman JD, Brychta RJ, McGehee S, Fletcher LA, Fink YA, Kapuria D, Cassimatis TM, Kelsey N, Cero C, Sater ZA, Piccinini F, Baskin AS, Leitner BP, Cai H, Millo CM, Dieckmann W, Walter M, Javitt NB, Rotman Y, Walter PJ, Ader M, Bergman RN, Herscovitch P, Chen KY, Cypess AM. Chronic mirabegron treatment increases human brown fat, HDL cholesterol, and insulin sensitivity. J Clin Invest. 2020 May 1;130(5):2209-2219. doi: 10.1172/JCI131126. https://pubmed.ncbi.nlm.nih.gov/31961826